Paradigm Biopharmaceuticals CEO Paul Rennie recently presented at the Ausbiz Capital Investor Connect Series, providing an overview of the company’s strategy and progress developing Zilosul® (injectable PPS) for osteoarthritis. The discussion covered the significant global unmet need in OA, the scientific rationale for iPPS, and the ongoing Phase 3 clinical trial, including the pathway toward the planned interim analysis at 50% patient completion expected in 2026.

For investors who were unable to attend, the full presentation is available to watch below.